Lessons from next generation influenza vaccines for inflammatory disease therapies

Daniel H. Zimmerman, R. E. Carambula, J. Ciemielewski, K. S. Rosenthal

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic ‘strains’ and inflammatory T cell responses, Th1 or Th17, that drive each person's disease. As such, next generation vaccine-like antigen specific therapies for inflammatory diseases can be developed but will need to be customized to the patient depending upon the antigen and T cell response that is driving the disease.

Original languageEnglish (US)
Article number105729
JournalInternational Immunopharmacology
StatePublished - Sep 2019
Externally publishedYes


  • Immunomodulation
  • Influenza
  • Rheumatoid arthritis
  • T cells
  • Vaccine therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Lessons from next generation influenza vaccines for inflammatory disease therapies'. Together they form a unique fingerprint.

Cite this